RESUMO
Proplast II disc implants (Vitek Inc, Houston) were used in nine patients (14 joints) who underwent discectomy of the temporomandibular joint (TMJ). These patients subsequently underwent removal of the implants from 10 to 28 months postplacement due to pain and occlusal changes or radiographic changes in the joints. Light and electron microscopic evaluations were performed on the retrieved implants and surrounding tissue. Evidence of gross deterioration manifested by fracture of the implant was present in 10 of the 14 implants, and microscopic evidence of deterioration was present in all implants. Foreign-body giant cell reaction in surrounding tissues and microfragmentation of the implant were evident in all joints.
Assuntos
Óxido de Alumínio , Alumínio , Cartilagem Articular/ultraestrutura , Reação a Corpo Estranho/patologia , Luxações Articulares/cirurgia , Politetrafluoretileno , Proplast/análogos & derivados , Próteses e Implantes , Transtornos da Articulação Temporomandibular/patologia , Articulação Temporomandibular/ultraestrutura , Adulto , Idoso , Materiais Biocompatíveis , Cartilagem Articular/cirurgia , Estudos de Avaliação como Assunto , Feminino , Reação a Corpo Estranho/etiologia , Humanos , Luxações Articulares/patologia , Masculino , Microscopia Eletrônica , Pessoa de Meia-Idade , Articulação Temporomandibular/cirurgia , Transtornos da Articulação Temporomandibular/cirurgiaRESUMO
By use of a modified heat-suction, skin blister technique, we found that oral hydroxyzine, 25 mg four times a day, inhibits antigen-induced ultrastructural changes of mast cells and in vivo histamine release in the skin of ragweed-sensitive individuals. To our knowledge this is the first demonstration that an orally active antihistamine can inhibit in vivo cutaneous anaphylactic reactions.
Assuntos
Antígenos/farmacologia , Liberação de Histamina/efeitos dos fármacos , Hidroxizina/farmacologia , Administração Oral , Adulto , Biópsia , Temperatura Alta , Humanos , Hidroxizina/administração & dosagem , Hipersensibilidade Tardia/imunologia , Mastócitos/imunologia , Métodos , Pele/patologia , SucçãoRESUMO
Storage of human erythrocytes in SAG media results in the release of membrane microvesicles with a diameter of about 190 nm. They can be separated from intact erythrocytes by centrifugation on a dextran barrier solution (density 1.078 g/l). Vesicles prepared from cold stored erythrocyte concentrates are like those released upon ATP depletion by erythrocytes incubated without glucose at 37 degrees C [15]. The course of vesiculation was followed by measuring acetylcholinesterase during storage of the erythrocyte concentrate for 35 days. Its activity remained constant within the storage units during the preservation period. This enzyme and phospholipids were released continuously in a proportional manner. The release of sialic acid amounted to about half of that of phospholipids. Owing to depletion of 2,3-bisphosphoglycerate the binding of ATP to haemoglobin increased and the concentration of free ATP declined. Addition of an ion-exchange resin to stored erythrocytes kept the pH constant, retarded the breakdown of 2,3-P2G and stabilized the concentration of free ATP. That inhibited the rate of irreversible vesiculation. Therefore, maintenance of 2,3-bisphosphoglycerate plus ATP during long-term storage of erythrocytes is a condition of keeping intact their membrane, metabolism and oxygen transport function.
